Sensome

Focus: Sensome is a France-based medical device company specializing in smart sensor technology for vascular and oncology interventions. The company operates at the intersection of interventional medicine and real-time diagnostic sensing.

Neurology Oncology

Profile data last refreshed 10h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Sensome

AI assessmentNot Hiring

No open roles listed right now. Follow Sensome to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Clotild Smart Guidewire System

Peripheral Vascular Disease

N/A

Clinical Trials (1)

NCT06112054Impedance Sensor Evaluated in Peripheral Artery Disease for Tissue Detection

N/A

Help build intelligence for Sensome

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Frontier deep-tech platform: sensor-based guidance systems represent an emerging category in interventional medicine with significant IP moat potential.
Clinical validation underway: 3 active trials across stroke, peripheral vascular disease, and lung cancer indicate progression toward regulatory and commercial milestones.
European innovation hub: based in France with public company status, offering potential stability and access to EU regulatory pathways and funding ecosystems.

Watch Out For

Zero current hiring: no active job postings signals potential restructuring, consolidation discussions, or capital constraints despite public status.
Early-stage clinical program: all 3 programs remain in pre-phase trial status with no clear phase progression or PDUFA visibility, creating execution risk.
Limited financial transparency: no revenue, R&D spend, or cash position data available in public filings examined, raising questions about sustainability and growth trajectory.

Generated by Claude from Sensome's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Clotild® Smart Guidewire System

Stroke

N/A

Clinical Trials (1)

NCT04993079Clotild® Smart Guidewire System (CSGS) Evaluation in EndovascUlar Thrombectomy Procedure

N/A

BioSpy System

Lung Cancer

N/A

Clinical Trials (1)

NCT06380361InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology

N/A